NeoGenomics, Inc. (NEO)
NeoGenomics, Inc. (NEO) is a healthcare company (diagnostics & research) based in the United States. The share price is $15.25, down 1.04% on the day, which values the company at $1.97B. Price as of 18 Nov 2026, 10:38 UTC, from Yahoo Finance.
Key facts
- Share price
- $15.25−1.04% today
- Market value
- $1.97B
- Forward P/E
- 48.5×
- Funk Score
- 44/100
- Against its own history
- Well below its usual priceusual price $29.07
- 200-week average
- $13.3914% above
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
NeoGenomics, Inc. in more detail
NEO trades at 48.5× next year's expected earnings, 2.5× sales. Measured against its own history, the price is 48% below what its usual multiples would imply ($29.07) — well below its usual price. It sits 14% above its 200-week average of $13.39.
Over the last five fiscal years NeoGenomics, Inc. has compounded revenue 10.4% a year. Its Funk Score is 44 out of 100 (financial strength 2.7, profitability 2.6, growth 7.5, value 4.7, each out of 10).
In its favour: Operating margin is expanding; Five straight years of revenue growth. Worth checking: Share count keeps rising; Thin interest cover.
NeoGenomics, Inc. (NEO): questions and answers
What is NEO's PEG ratio?
NeoGenomics, Inc.'s PEG ratio is 2.09 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is NeoGenomics, Inc.'s market cap?
NeoGenomics, Inc. is valued at $1.97B at a share price of $15.25.
Is NEO overvalued or undervalued?
Against its own history, NEO is well below its usual price: the price is 48% below the $29.07 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is NEO above its 200-week moving average?
Yes. NEO is 13.9% above its 200-week average of $13.39. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is NeoGenomics, Inc. growing?
Over the last five fiscal years NeoGenomics, Inc.'s revenue grew 10.4% a year; over ten years revenue grew 64.5% a year.
Does NEO pay a dividend?
NeoGenomics, Inc. does not currently pay a regular dividend.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “NeoGenomics, Inc. (NEO) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/NEO
Underlying data: Yahoo Finance; company filings with the SEC.